VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) is scheduled to present at the Virus-Like Particle and Nano-Particle Vaccines (“VLPNPV”) Conference on Friday, June 24 at 9:00 AM CEDT (3:00 AM ET). The event is being held at the Leiden University Medical Center in the Netherlands.
During the presentation, Customized Vaccine Design and Antigen Delivery through Novel Enveloped Virus-like Particles, Dr. Marc Kirchmeier, Ph.D., VBI’s Vice President of Formulation Development, will provide an overview of VBI’s eVLP Platform and will summarize recent developments in the company’s pipeline of eVLP Platform-derived vaccine candidates.
VBI’s eVLP Platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines. eVLPs are an innovative new class of synthetic vaccines that closely mimic the target virus to elicit a potent immune response. eVLPs are highly customizable, which allows VBI to rationally design preventative or therapeutic vaccine candidates by controlling the expression of both surface and internal target proteins of interest. VBI is advancing a pipeline of eVLP vaccines with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”).
Now in its third year, the VLPNPV Conference attracts scientists and international researchers interested in virus-like particles, as well as contributors from academic programs and regulatory groups. For more information, visit: http://bit.ly/vlpnpv-2016.
- Event: 2016 Virus-Like Particle and Nano-Particle Vaccines Conference
- Date: Friday, June 24, 2016
- Time: 9:00 AM CEDT (3:00 AM ET)
- Location: Leiden University Medical Center in the Netherlands
- Event Website: http://bit.ly/vlpnpv-2016
VBI Vaccines Inc. (“VBI”) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac™, a hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac is approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation (collectively, “forward-looking statements”) that may not be based on historical fact, but instead relate to future events, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements.
Such forward-looking statements are based on a number of assumptions, including assumptions regarding the successful development and/or commercialization of the company’s products, including the receipt of necessary regulatory approvals; general economic conditions; competitive conditions; and changes in applicable laws, rules and regulations.
VBI cautions the reader that forward-looking statements and information involve known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements or information contained in this news release and VBI has made assumptions and estimates based on or related to many of these factors.
Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on the company’s current expectations, and the company undertakes no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.